不确定期慢性HBV感染者的分布与治疗

张会; 王欣茹; 肖丽; 咸建春

doi:10.3969/j.issn.1001-5256.2021.12.008

不确定期慢性HBV感染者的分布与治疗

DOI: 10.3969/j.issn.1001-5256.2021.12.008

泰州市人民医院肝病科，江苏泰州 225300

基金项目:

泰州市科技支撑(社会发展)项目 (TS201813);

泰州市人民医院院级课题 (ZD201905)

详细信息

通信作者:
咸建春，xianjc09@163.com

中图分类号: R512.62
计量
- 文章访问数: 403
- HTML全文浏览量: 63
- PDF下载量: 85
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-17
- 录用日期: 2021-09-17
- 出版日期: 2021-12-20

Distribution and treatment of patients in the indeterminate phase of chronic hepatitis B virus infection

Department of Hepatology, Taizhou People's Hospital, Taizhou, Jiangsu 225300, China

Research funding:

Taizhou Science and Technology(Social Development) （TS201813）

The College Project of Taizhou People's Hospital （ZD201905）

摘要

- 乙型肝炎病毒 /
- 乙型肝炎，慢性 /
- 不确定期 /
- 治疗学
- Hepatitis B Virus /
- Hepatitis B, Chronic /
- Indeterminate Phrase /
- Therapeutic

HTML全文

参考文献(10)

[1]	DI BISCEGLIE AM, LOMBARDERO M, TECKMAN J, et al. Determination of hepatitis B phenotype using biochemical and serological markers[J]. J Viral Hepat, 2017, 24(4): 320-329. DOI: 10.1111/jvh.12643.
[2]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[3]	YAO K, LIU J, WANG J, et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone[J]. J Viral Hepat, 2021, 28(7): 1025-1033. DOI: 10.1111/jvh.13511.
[4]	HSU YN, PAN CQ, ABBASI A, et al. Clinical presentation and disease phases of chronic hepatitis B using conventional versus modified ALT criteria in Asian Americans[J]. Dig Dis Sci, 2014, 59(4): 865-871. DOI: 10.1007/s10620-014-3054-1.
[5]	TERRAULT NA, LOK ASF, McMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
[6]	HUANG DQ, LI X, LE MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase[J]. Clin Gastroenterol Hepatol, 2021. DOI: 10.1016/j.cgh.2021.01.019. [Online ahead of print]
[7]	CHOI GH, KIM GA, CHOI J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation[J]. Aliment Pharmacol Ther, 2019, 50(2): 215-226. DOI: 10.1111/apt.15311.
[8]	BUSCH K, THIMME R. Natural history of chronic hepatitis B virus infection[J]. Med Microbiol Immunol, 2015, 204(1): 5-10. DOI: 10.1007/s00430-014-0369-7.
[9]	ORMECI A, AYDIN Y, SUMNU A, et al. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels[J]. Int J Infect Dis, 2016, 52: 68-73. DOI: 10.1016/j.ijid.2016.09.007.
[10]	DUAN M, CHI X, XIAO H, et al. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B[J]. Hepatol Int, 2021, 15(2): 318-327. DOI: 10.1007/s12072-021-10153-2.